Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

LOS ANGELES–(BUSINESS WIRE)–Puma has been notified by the FDA that its IND has been reviewed, and Puma can proceed with clinical development of alisertib monotherapy for SCLC.

Recent Articles